Angiotensin-receptor blockers and the risk of alzheimer´s disease: A meta-analysis

Teodoro J. Oscanoa, José Amado, Xavier Vidal, Roman Romero-Ortuno

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Background: Anti-hypertensive medications may reduce the incidence of cognitive disorders. This may be due to reasons beyond their pure hypotensive effect. This study aimed to systematically review the association between the use of Angiotensin-Receptor Blockers (ARBs) and the incidence of Alzheimer’s disease (AD). Methods: We systematically searched studies reporting the association between ARB use and the incidence of AD. Results: Ten studies (1 RCT, 2 case-control and 7 cohort studies) met the inclusion criteria. When all observational studies (9) were analyzed, ARB use was associated with a reduced risk of incident AD (HR 0.72, 95% CI: 0.58-0.88, p<0.001). In the only RCT, decrease in the incidence of AD was also significant (HR= 0.31, 95% CI: 0.14-0.68). Conclusion: ARB use may reduce the risk of incident AD. This association does not imply causation and further research is required to clarify potential mechanisms.

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalCurrent Reviews in Clinical and Experimental Pharmacology
Issue number1
StatePublished - 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 Bentham Science Publishers.


  • Alzheimer´s disease
  • Angiotensin II
  • Angiotensin-receptor blockers
  • Elderly
  • Meta-analysis
  • Pro-oxidant effects


Dive into the research topics of 'Angiotensin-receptor blockers and the risk of alzheimer´s disease: A meta-analysis'. Together they form a unique fingerprint.

Cite this